98%
921
2 minutes
20
Background & Aims: Nonvariceal upper gastrointestinal bleeding (NVUGIB) is a common and potentially life-threatening condition. Over-the-scope clips (OTSCs) have emerged as a promising endoscopic treatment option for NVUGIB. We aimed to analyze the efficacy and safety of OTSCs compared to standard endoscopic treatments (ST) in patients with NVUGIB.
Methods: We conducted a comprehensive search of PubMed, Embase, Scopus, and Cochrane Library databases from inception to June 2024 for randomized controlled trials (RCTs) comparing OTSCs with ST for NVUGIB. The primary outcomes were initial hemostasis and persistent bleeding. Secondary outcomes included rebleeding rates, mortality, hospital stays and others. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random/fixed-effects models.
Results: Six RCTs involving 621 patients were included in the meta-analysis. OTSCs demonstrated significantly higher initial hemostasis (OR 4.80, 95% CI 1.78-12.96; P = 0.002) and lower persistent bleeding rates (OR 0.17, 95% CI 0.05-0.56; P = 0.003) compared to ST group. The rebleeding rate was significantly lower in the OTSC group 7-days re-bleeding (OR 0.27, 95% CI 0.14-0.53; P = 0.001); 30-days rebleeding (OR 0.40, 95%CI 0.22, 0.70; P = 0.002). No significant differences were observed in mortality (OR 0.65, 95% CI 0.31-1.33; P = 0.38) and hospital stay (mean difference 0.79 days 95%CI -0.57, 2.15) between the two groups.
Conclusions: OTSCs are more effective than ST for achieving hemostasis and preventing rebleeding in patients with NVUGIB, without increasing mortality. Key message What is Already Known Previous studies have shown that nonvariceal upper gastrointestinal bleeding (NVUGIB) is a serious medical condition that needs effective endoscopic interventions. The success rates of standard treatments for achieving hemostasis and preventing rebleeding are not consistent. What This Study Adds According to this study, over-the-scope clips (OTSCs) have the same mortality rate as standard endoscopic treatments, but they significantly improve initial hemostasis and lower rebleeding rates. Impact on Research, Practice, or Policy The findings support the use of OTSCs as a preferred intervention for NVUGIB, which could affect clinical guidelines and encourage additional research focused on improving endoscopic techniques and patient outcomes in the management of gastrointestinal bleeding.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/postmj/qgae155 | DOI Listing |
Scand J Trauma Resusc Emerg Med
September 2025
Department of Clinical Sciences, Malmö, Section of Surgery, Lund University, Malmö, Sweden.
Background: Antithrombotic treatment might affect bleeding symptoms, identification of bleeding source and treatment for patients with acute gastrointestinal bleeding. This study aims to investigate possible differences in initial bleeding symptoms, identified bleeding site and treatment of patients with or without antithrombotic medication admitted for gastrointestinal bleeding.
Methods: All consecutive adult patients primarily admitted for gastrointestinal bleeding at Skane University Hospital between 2018-01-01 and 2019-06-31, were included in this study.
Nihon Shokakibyo Gakkai Zasshi
September 2025
Department of Gastrointestinal Surgery, Mie Chuo Medical Center.
We report a case of vascular Ehlers-Danlos syndrome in a 30-year-old male patient. He presented to his local doctor with sudden onset of epicardial pain at around 5:00 p.m.
View Article and Find Full Text PDFJ Thorac Cardiovasc Surg
September 2025
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota. Electronic address:
Introduction: Goals of left ventricular assist device (LVAD) therapy includes low rates of right ventricular failure (RVF) and favorable survival outcomes. However, conventional metrics often fail to capture its physiologic complexity. We evaluated the prognostic utility of the Active Cardiac Index (ActCI) and Passive Cardiac Index (PasCI)-which reflect cardiac output driven by active RV contractility and passive venous return, respectively.
View Article and Find Full Text PDFEur J Gastroenterol Hepatol
August 2025
Department of Gastroenterology and Hepatology, Noordwest Ziekenhuisgroep, Alkmaar.
Currently, symptomatic gastrointestinal (GI) angiodysplasia is treated with argon plasma coagulation (APC) via endoscopic procedures, supplemented with octreotide or thalidomide treatment. However, suboptimal response and side effects are often seen. Bevacizumab, an angiogenesis inhibitor, may provide an alternative systemic therapy for patients with refractory GI angiodysplasia.
View Article and Find Full Text PDFArq Gastroenterol
September 2025
Alimentary Tract Research Center, Clinical Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Background: Acute upper gastrointestinal bleeding (AUGIB) is a critical medical emergency and is a common cause of illness and death in individuals with liver cirrhosis.
Objective: The point of this study was to check how well the albumin-to-bilirubin ratio (ALBI) and model for end-stage liver disease (MELD) scores could predict how these patients would do in the future.
Methods: The Imam Khomeini Hospital gastroenterology department conducted a retrospective examination.